Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] gained 6.96% or 0.51 points to close at $7.84 with a heavy trading volume of 2769641 shares.
The daily chart for BCRX points out that the company has recorded 21.74% gains over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 1.93M shares, BCRX reached to a volume of 2769641 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Biocryst Pharmaceuticals Inc [BCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $14.82 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 1.18. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Biocryst Pharmaceuticals Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 20, 2023. While these analysts kept the previous recommendation, RBC Capital Mkts dropped their target price from $9 to $10. The new note on the price target was released on September 18, 2023, representing the official price target for Biocryst Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $11, while Jefferies analysts kept a Buy rating on BCRX stock.
The Average True Range (ATR) for Biocryst Pharmaceuticals Inc is set at 0.38, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 3.94.
Trading performance analysis for BCRX stock
Biocryst Pharmaceuticals Inc [BCRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.53. With this latest performance, BCRX shares gained by 11.13% in over the last four-week period, additionally plugging by 21.74% over the last 6 months – not to mention a rise of 27.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 55.65, with the RSI for the last a single of trading hit 60.49, and the three-weeks RSI is set at 53.51 for Biocryst Pharmaceuticals Inc [BCRX]. The present Moving Average for the last 50 days of trading for this stock 7.58, while it was recorded at 7.45 for the last single week of trading, and 6.65 for the last 200 days.
Biocryst Pharmaceuticals Inc [BCRX]: A deeper dive into fundamental analysis
Biocryst Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.73 and a Current Ratio set at 2.78.
Biocryst Pharmaceuticals Inc [BCRX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Biocryst Pharmaceuticals Inc posted -0.28/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.06. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Biocryst Pharmaceuticals Inc go to 44.80%.
An analysis of Institutional ownership at Biocryst Pharmaceuticals Inc [BCRX]
There are presently around $86.00%, or 86.99%% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 19.96 million shares, which is approximately 9.6845%. VANGUARD GROUP INC, holding 18.77 million shares of the stock with an approximate value of $$116.0 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $$77.68 million in BCRX stock with ownership which is approximately 6.1%.
